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Abstract: Intravascular activation of coagulation is observed in acute pancreatitis and is related to
the severity of this inflammation. The aim of our study was to evaluate the impact of acenocoumarol
therapy on the course of acute pancreatitis induced in male rats by pancreatic ischemia followed by
reperfusion. Acenocoumarol at a dose of 50, 100, or 150 µg/kg/dose was administered intragastrically
once a day, starting the first dose 24 h after the initiation of pancreatic reperfusion. Results:
Histological examination showed that treatment with acenocoumarol reduces pancreatic edema,
necrosis, and hemorrhages in rats with pancreatitis. Moreover, the administration of acenocoumarol
decreased pancreatic inflammatory infiltration and vacuolization of pancreatic acinar cells. These
findings were accompanied with a reduction in the serum activity of lipase and amylase, concentration
of interleukin-1β, and plasma D-Dimer concentration. Moreover, the administration of acenocoumarol
improved pancreatic blood flow and pancreatic DNA synthesis. Acenocoumarol given at a dose of
150 µg/kg/dose was the most effective in the treatment of early phase acute pancreatitis. However
later, acenocoumarol given at the highest dose failed to exhibit any therapeutic effect; whereas
lower doses of acenocoumarol were still effective in the treatment of acute pancreatitis. Conclusion:
Treatment with acenocoumarol accelerates the recovery of ischemia/reperfusion-induced acute
pancreatitis in rats.
Int. J. Mol. Sci. 2017, 18, 882; doi:10.3390/ijms18040882 www.mdpi.com/journal/ijms
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1. Introduction
Coagulation is one of the mechanisms of hemostasis. Its activation causes clot formation to
prevent blood loss from a damaged vessel. Coagulation disorders may take the form of insufficient
or excessive clotting. Insufficient clotting can result in bleeding or hemorrhage; whereas excessive
activation of clotting can lead to thrombosis and/or disseminated intravascular coagulation (DIC).
Moreover, coagulation leads to the activation of inflammatory processes. Created during coagulation,
thrombin and the complex of tissue factor plus active factor VII can stimulate protease activated
receptors (PARs) [1,2]. This in turn can induce the expression of adhesion molecules leading to
leukocyte-mediated injury [3,4]. Moreover, thrombin activates the production of monocyte chemotactic
protein-1 (MCP-1) and pro-inflammatory interleukin-6 in fibroblasts, epithelial cells, and mononuclear
cells [5]. The inflammatory response is also induced by the CD40 ligand released from activated
platelets. The CD40 ligand stimulates the synthesis of the tissue factor and increases the level of
pro-inflammatory interleukin-6 and interleukin-8 [3,6].
On the other hand, the relationship between coagulation and inflammation is bidirectional and
is based on positive feedback. Activation of the coagulation induces inflammation, but at the same
time the development of the inflammatory process activates the clotting cascade. Pro-inflammatory
cytokines play an important role in the activation of coagulation by increasing expression of the tissue
factor on monocytes and endothelium [6]. Moreover, inflammation reduces the activity of natural
anticoagulants and inhibits fibrinolysis [3,4].
Coagulative disorders are also known to occur in acute pancreatitis and are related to the severity
of this disease. In mild acute pancreatitis, the scattered intravascular thrombosis is observed in local
pancreatic circulation; whereas severe acute pancreatitis may lead to the development of disseminated
intravascular coagulation (DIC) [7–10]. Measurement of disseminated intravascular coagulation
parameters is useful in the assessment of acute pancreatitis severity and has a prognostic value [9,10].
Previous experimental and clinical studies have shown the protective and therapeutic effect of
heparin in acute pancreatitis [11–16]. Treatment with heparin has been also found to be effective in the
prevention of pancreatitis-evoked encephalopathy [17]. Moreover, treatment with recombinant human
soluble thrombomodulin seems to be useful in preventing walled-off necrosis in patients with severe
acute pancreatitis [18].
In harmony with those findings is the observation that the inhibition of coagulation by
pretreatment with low doses of acenocoumarol, a vitamin K antagonist, exhibits a protective effect on
the pancreas and inhibits the development of acute pancreatitis induced by ischemia/reperfusion [19]
or cerulein [20]. However, from a clinical point of view, it is more important to determine whether the
administration of acenocoumarol after the development of acute pancreatitis exhibits any therapeutic
effect on this disease. Therefore, the aim of this study was to answer the above stated question.
2. Results
2.1. International Normalized Ratio (INR) Value
In control saline-treated sham-operated rats without induction of acute pancreatitis, the
prothrombin time measured as the international normalized ratio (INR) reached a value of 1.14 ± 0.10
(Figure 1). Induction of acute pancreatitis by pancreatic ischemia followed by reperfusion led to
an increase in INR and this effect was statistically significant between the 6th hour and 9th day of
pancreatic reperfusion.
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Treatment with acenocoumarol after the induction of acute pancreatitis additionally increased
INR. In the case of acenocoumarol administered at a dose of 100 or 150 µg/kg/day, this effect reached
a statistical significance on the second day of pancreatic reperfusion (1 day after the first dose of
acenocoumarol). In the case of acenocoumarol administered at a dose of 50 µg/kg/day, this effect
was statistically insignificant until the 5th day of reperfusion. Nine days after the start of pancreatic
reperfusion, in rats treated with acenocoumarol given at a dose of 50, 100, or 150 µg/kg/day, the
INR reached a value of 3.05, 3.82 or 5.92, respectively. At the 14th day of pancreatic reperfusion, the
effects of treatment with acenocoumarol on the INR value in rats with ischemia/reperfusion-induced
pancreatitis were similar to those observed at the 9th day of pancreatic reperfusion (Figure 1).Int. J. Mol. Sci. 2017, 18, 882 3 of 18 
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Figure 1. Influence of the treatment with acenocoumarol (ACN) on the prothrombin time expressed 
as the international normalized ratio (INR) in the course of ischemia/reperfusion-induced acute 
pancreatitis (IR). ACN was given at a dose of 50, 100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 
150). Mean ± SEM. n = 8 rats in each experimental group. a p < 0.05 compared to control rats without 
induction of acute pancreatitis (C), b p < 0.05 compared to rats with IR without treatment with ACN 
at the same time of observation. 
2.2. Histological Examination 
Pancreatic ischemia followed by reperfusion induced severe acute pancreatitis in all rats subject to 
this procedure. Macroscopic examination of the lung, liver, and kidney did not show any injury of those 
organs in the course of ischemia/reperfusion-induced pancreatitis. Maximal histological damage of 
pancreatic tissue was observed between the 1st and 2nd day of pancreatic reperfusion (Table 1, Figure 
2). One day after the start of pancreatic reperfusion, moderate or severe inter- and intralobular edema 
was accompanied by moderate perivascular or abundant diffuse leukocyte infiltrations of the 
pancreatic tissue. The percentage of acinar cells with vacuolization was between less than 25% to 50% 
of these cells. Necrosis ranged from less than 15% to 35% of acinar cells. Moreover, 3 to 5 foci of 
hemorrhage were observed in each slide (Table 1, Figure 2). On subsequent days, the spontaneous 
regeneration of pancreatic tissue was observed. At the 14th day of pancreatic reperfusion, histological 
signs of pancreatic tissue damage were limited to a slight interlobular edema and minimal 
inflammatory perivascular infiltration. Vacuolization of acinar cells ranged between 0 to less than 25% 
of those cells. 
Treatment with acenocoumarol accelerated pancreatic regeneration in the course of 
ischemia/reperfusion-induced acute pancreatitis and this effect depended on the dose of acenocoumarol 
(Table 1). The first signs of pancreatic histology improvement were observed 1 day after the 
administration of the first dose of acenocoumarol. (Table 1). In the case of acenocoumarol given at a dose 
of 50 µg/kg/dose, one-day treatment with this coumarin only led to a slight decrease in the number of cells 
undergoing necrosis (Table 1, Figure 3). At the 5th day of pancreatic reperfusion, administration of 
acenocoumacol given at a dose of 50 µg/kg/dose had no effect on pancreatic morphology; whereas at the 
9th day of reperfusion, the therapeutic effect of this dose of acenocoumarol was pronounced. A reduction 
in pancreatic edema, inflammatory infiltration, and number of hemorrhagic foci was observed. These 
effects led to a statistically significant reduction in the total histological score of pancreatic damage (Figure 
2). At the 14th day of reperfusion, acenocoumarol administered at a dose of 50 µg/kg/day eliminated 
pancreatic edema and reduced inflammatory infiltration of pancreatic tissue. In this time of observation, 
Figure 1. Influence of the treat ent ith acenocou arol ( C ) on the prothro bin ti e expressed
as the international nor alized ratio (I R) in the course of ische ia/reperfusion-induced acute
pancreatitis (IR). ACN was given at a dose of 50, 100, or 150 µg/kg/day (ACN 50, ACN 100, or
ACN 150). Mean ± SEM. n = 8 rats in each experimental group. a p < 0.05 compared to control rats
without induction of acute pancreatitis (C), b p < 0.05 compared to rats with IR without treatment with
ACN at the same time of observation.
2.2. istological Exa ination
Pancreatic ischemia followed by reperfusion induced sev re acute pancreatitis in all rats subject
to this procedure. Macroscopic examination of the lung, liver, and ki ney did not show any injury of
those organs in the course of ischemia/reperfusion-in uced pancreatitis. Maximal histologic l d mage
of pancreatic tissue wa observ d b twe n the 1st and 2nd day of pancreatic reperfusion (Table 1,
Figur 2). One day after the start of pancreatic reperfusion, m derat or severe inter- nd intralobular
edema was ccompanied by moderate perivascul r or abun ant diffuse leukocyte infiltrations of
the pancreatic tissu . The perc ntage of a inar cells with vacuolization as between less than 25
to 50% of these cell . Necrosis ranged from less than 15% to 35% of acinar c lls. Moreover, 3 to
5 foci of hemo rhage w re observed in each slide (Table 1, Fig re 2). On subsequent days, the
spo taneous regeneration of pancreatic tissue was observed. At the 14th day of ancreatic reperfusion,
histological signs of pancr atic tissu damage were limited to a sligh interlobular dem and ini al
infla atory perivascular infiltration. Vacuolization of acinar cells ranged bet een 0 to le s than 25%
of those cells.
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Treatment with acenocoumarol accelerated pancreatic regeneration in the course of
ischemia/reperfusion-induced acute pancreatitis and this effect depended on the dose of
acenocoumarol (Table 1). The first signs of pancreatic histology improvement were observed 1 day
after the administration of the first dose of acenocoumarol. (Table 1). In the case of acenocoumarol
given at a dose of 50 µg/kg/dose, one-day treatment with this coumarin only led to a slight
decrease in the number of cells undergoing necrosis (Table 1, Figure 3). At the 5th day of pancreatic
reperfusion, administration of acenocoumacol given at a dose of 50 µg/kg/dose had no effect on
pancreatic morphology; whereas at the 9th day of reperfusion, the therapeutic effect of this dose of
acenocoumarol was pronounced. A reduction in pancreatic edema, inflammatory infiltration, and
number of hemorrhagic foci was observed. These effects led to a statistically significant reduction in the
total histological score of pancreatic damage (Figure 2). At the 14th day of reperfusion, acenocoumarol
administered at a dose of 50 µg/kg/day eliminated pancreatic edema and reduced inflammatory
infiltration of pancreatic tissue. In this time of observation, the therapeutic effect of acenocoumarol
given at a dose of 50 µg/kg/day was similar to that observed after acenocoumarol given at a dose of
100 µg/kg/day (Table 1, Figures 2 and 4).
Table 1. Influence of the treatment with acenocoumarol (ACN) on pancreatic morphological signs of
pancreatic damage in the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was
given at a dose of 50, 100 or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150).
Experimental Groups Edema(0–3)
Inflammatory
Infiltration
(0–3)
Vacuolization
(0–3)
Necrosis
(0–3)
Hemorrhages
(0–3)
Control 0 0 0 0 0
I/R (6 h) 2–3 1–2 1 1 1–2
I/R (1 day) 2–3 3 1–2 1–2 2
I/R (2 days)
Saline 2 3 1 1–2 2
ACN 50 2 3 1 1 2
ACN 100 2 2–3 1 0–1 1–2
ACN 150 2 2–3 1 0–1 1–2
I/R (5 days)
Saline 1–2 2 1 1 0–1
ACN 50 1–2 2 1 1 0–1
ACN 100 1 1–2 1 1 0–1
ACN 150 1 1–2 1 1 0–1
I/R (9 days)
Saline 1 2 0–1 0 0–1
ACN 50 0–1 1–2 0–1 0 0
ACN 100 0–1 1 0 0 0
ACN 150 1 2 0 0 1
I/R (14 days)
Saline 1 1 0–1 0 0
ACN 50 0 0–1 0 0 0
ACN 100 0 0–1 0 0 0
ACN 150 1 1 0 0 0–1
Numbers represent the predominant histological grading in each experimental group.
Acenocoumarol administered at a dose of 100 µg/kg/day caused the greatest improvement in the
morphology of the pancreas. One-day treatment with this dose of acenocoumarol resulted in a decrease
in pancreatic necrosis, inflammatory infiltration, and the number of foci of hemorrhage, leading to
a significant reduction in the total histological score of pancreatic damage (Table 1, Figures 2 and 3).
The beneficial effect of acenocoumarol given at a dose of 100 µg/kg/day was also observed at the 5th,
9th, and 14th day of reperfusion as a reduction in pancreatic edema, inflammatory infiltration, and
vacuolization of acinar cells (Table 1, Figures 2 and 4). At the 9th day of reperfusion, acenocoumarol,
given at a dose of 100 µg/kg/day, further reduced the number of hemorrhagic foci (Table 1).
Int. J. Mol. Sci. 2017, 18, 882 5 of 19Int. J. Mol. Sci. 2017, 18, 882 5 of 18 
0
2
4
6
8
10
12
a,b
a
      C        6 h     1 day          2 days                   5 days                   9 days                 14 days
a
      TIME AFTER INDUCTION OF IR
control (C)
IR
IR + ACN 50
IR + ACN 100
IR + ACN 150
a
a
a
a,b
a,b
a
a,b
a
a
a
a,c
a
b
a,c,d
b
To
ta
l h
is
to
lo
gi
ca
l s
co
re
 
Figure 2. Influence of the treatment with acenocoumarol (ACN) on the total histological score of 
pancreatic damage in the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was 
given at a dose of 50, 100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats 
in each experimental group. a p < 0.05 compared to control rats without induction of acute pancreatitis 
(C), b p < 0.05 compared to rats with IR without treatment with ACN at the same time of observation; 
c p < 0.05 compared to IR + ACN 100 at the same time of observation; d p < 0.05 compared to IR + ACN 
50 at the same time of observation. 
 
Figure 3. Representative morphological features of the pancreas observed after two-day pancreatic 
reperfusion in the course of ischemia/reperfusion-induced acute pancreatitis. (A) rats treated with 
saline; (B) rats treated with acenocoumarol given at a dose of 50 µg/kg/day; (C) rats treated with 
acenocoumarol given at a dose of 100 µg/kg/day; (D) rats treated with acenocoumarol given at a dose 
of 150 µg/kg/day. Hematoxylin-eosin counterstain. Original magnification 200×. 
Figure 2. Influence of the treatment with acenocoumarol (ACN) on the total histological score of
pancreatic damage in the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was
given at a dose of 50, 100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM.
n = 8 rats in each experimental group. a p < 0.05 compared to control rats without induction of acute
pancreatitis (C), b p < 0.05 compared to rats with IR without treatment with ACN at the same time of
observation; c p < 0.05 compared to IR + ACN 100 at the same time of observation; d p < 0.05 compared
to IR + ACN 50 at the same time of observation.
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Figure 3. Representative morphological features of the pancreas observed after two-day pancreatic 
reperfusion in the course of ischemia/reperfusion-induced acute pancreatitis. (A) rats treated with 
saline; (B) rats treated with acenocoumarol given at a dose of 50 µg/kg/day; (C) rats treated with 
acenocoumarol given at a dose of 100 µg/kg/day; (D) rats treated with acenocoumarol given at a dose 
of 150 µg/kg/day. Hematoxylin-eosin counterstain. Original magnification 200×. 
Figure 3. Representative orphological features of the pancreas observed after t o-day pancreatic
reperfusion in the course of ische ia/reperfusion-induced acute pancreatitis. (A) rats treated ith
saline; (B) rats treated with acenocou arol given at a dose of 50 µg/kg/day; (C) rats treated ith
acenocou arol given at a dose of 100 µg/kg/day; ( ) rats treated ith acenocou arol given at a dose
of 150 µg/kg/day. Hematoxylin-eosin counterstain. Original magnification 200 .
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Figure 1. Representative morphological features of the pancreas observed after 14 day pancreatic
reperfusion in the course of ischemia/reperfusion-induced acute pancreatitis. (A) Rats treated with
saline; (B) rats treated with acenocoumarol given at a dose of 50 µg/kg/day; (C) rats treated with
acenocoumarol given at a dose of 100 µg/kg/day; (D) rats treated with acenocoumarol given at a dose
of 150 µg/kg/day. Hematoxylin-eosin counterstain. Original magnification 200×.
The abovementioned error in the original article did not have a material impact on the final results
and conclusions of our papers. We apologize to our readers for this inconvenience.
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Figure 4. Representative morphological features of the pancreas observed after fourteen-day pancreatic
reperfusion in the course of ischemia/reperfusion-induced acute pancreatitis. (A) rats treated with
saline; (B) rats treated with acenocoumarol given at a dose of 50µg/kg/day; (C) rats treated with
acenocoumarol given at a dose of 100 µg/kg/day; (D) rats treated with acenocoumarol given at a dose
of 150 µg/kg/day. Hematoxylin-eosin counterstain. Original magnification 200×.
In the case of acenocoumarol given at a dose of 150 µg/kg/day, a pronounced therapeutic effect
was also observed at the 2nd and 5th day of pancreatic reperfusion, and this effect was similar to
that observed after ac nocoum rol given a a dose of 100 µg/kg/day (Table 1, Figures 2 and 3).
Starting from the 9th day of reperfusion, acenocoumarol given at a dose of 150 µg/kg/day was
without any ben ficial effect on pancreatic edema or inflammatory infiltration, Moreover, at the 9th
and 14th day of pancreatic reperfusion, this dose of acenocoumarol resulted in an increase in the
number of hemorrhagic foci in comparison to the value observed in the control group (Table 1). These
effects led to a statistically significant increase in the total histological score of pancreatic damage at the
9th and 14th day of reperfusion in rats treat d with acenocou arol given at a dose of 150 µg/kg/day
in comparison to pancreatic damage observed in rats treated with acenocoumarol given at a dose
of 100 µg/kg/day (the 9th day) or rats treated with acenocoumarol given at a dose of either 50 or
100 µg/kg/day (the 14th day) (Figure 2).
2.3. Pancreatic Blood Flow
Acute ischemia/reperfusion-induced pancreatitis resulted in an immediate dramatic reduction
in pancreatic blood flow. After 6- and 24-h reperfusion, pancreatic blood flow was decreased by
approximately 60% and 80%, respectively, as compared to the control group (Figure 5). This negative
effect of ischemia/reperfusion-induced pancreatitis on pancreatic blood flow was not permanent and
starting from the second day of reperfusion, this parameter spontaneously and gradually improved,
reaching 87% of the control value on day 14. The administration of acenocoumarol affected pancreatic
blood flow in the course of ischemia/reperfusion-induced pancreatitis. At the beginning of pancreatic
reperfusion, all doses of acenocoumarol improved pancreatic blood flow. This effect was statistically
significant at the second day of reperfusion after the administration of acenocoumarol at doses of 100
or 150 µg/kg/day. In the case of acenocoumarol given at a dose of 50 µg/kg/day, the statistically
significant improvement of pancreatic blood flow was observed from the 5th day of pancreatic
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reperfusion. At the 9th day of reperfusion, acenocoumarol given at doses of 50 or 100 µg/kg/day
significantly improved pancreatic blood flow in rats with ischemia/reperfusion-induced acute
pancreatitis and pancreatic blood flow in these groups of animals reached a value similar to that
observed in control rats without the induction of pancreatitis. In contrast, the administration of
acenocoumarol at a dose of 150 µg/kg/day was without any beneficial effect on pancreatic blood
flow at the 9th day of reperfusion (Figure 5) and pancreatic blood flow in this group of animals was
statistically lower than that observed in rats treated with acenocoumarol at a dose of 100 µg/kg/day.
A similar lack of a beneficial effect of acenocoumarol given at a dose of 150 µg/kg/day on pancreatic
blood flow was also observed at the 14th day of pancreatic reperfusion (Figure 5).Int. J. Mol. Sci. 2017, 18, 882 7 of 18 
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Figure 5. Influence of treatment with acenocoumarol (ACN) on pancreatic blood flow in the course of 
ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, or 150 
µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group. a p < 
0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to rats with 
IR without treatment with ACN at the same time of observation; c p < 0.05 compared to IR + ACN 50 at 
the same time of observation; d p < 0.05 compared to IR + ACN 100 at the same time of observation. 
2.4. Serum Level of Amylase and Lipase 
As demonstrated in Figures 6 and 7, the development of acute ischemia/reperfusion-induced 
pancreatitis led to an increase in serum activity of amylase and lipase. Maximal serum activity of 
amylase was observed after one-day reperfusion of the pancreas. At that time, the activity of amylase 
was almost thirteen times greater than the value in control animals without induction of acute 
pancreatitis (Figure 6). The greatest activity of lipase was observed after a two-day reperfusion, 
reaching a value of more than twenty times greater than in the control group (Figure 7). Then serum 
activity of pancreatic enzymes spontaneously and gradually came down. The level of enzymes close 
to that in the control group was achieved two weeks following the start of pancreatic reperfusion. 
Treatment with acenocoumarol accelerated the normalization of serum amylase activity. This effect 
appeared for the first time at the 5th day of reperfusion. The effect of all doses of acenocoumarol was 
statistically significant; however, the highest dose of 150 µg/kg/day was the most effective. Four days 
later, low doses of acenocoumarol, 50 and 100 µg/kg/day, were still able to reduce the serum level of 
amylase, whereas the highest dose of acenocoumarol, 150µg/kg/day, was without a notable effect on 
this parameter. Two weeks after the start of reperfusion, treatment with any dose of acenocoumarol 
failed to significantly affect the serum activity of amylase (Figure 6). 
A similar effect of treatment with acenocoumarol was observed in the case of the serum activity of 
lipase (Figure 7). The first marked impact of acenocoumarol administration was observed at the 5th day 
of pancreatic reperfusion. Acenocoumarol given at doses of 100 or 150 µg/kg/day significantly reduced 
the pancreatitis-evoked increase in the serum activity of lipase. In contrast, acenocoumarol given at a dose 
of 50 µg/kg/day failed to markedly affect the serum activity of lipase in this time of observation (Figure 
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Figure 5. Influence of treatme acenocoumarol (ACN) on pancreatic blood flow in the course
of isc reperfusio -induced acute pancreatitis (IR). ACN was given at a dose of 50, 1 0, or
150 kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each xperimental group.
a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared
to rats with IR without treatment with ACN at the same time of observation; c p < 0.05 compared to
IR + ACN 50 at the same time of observation; d p < 0.05 compared to IR + ACN 100 at the same time
of observation.
2.4. Serum Level of Amylase and Lipase
As demonstrated in Figures 6 and 7, the development of acute ischemia/reperfusion-induced
pancreatitis led to an incr ase in serum acti ity of amylase and lipase. Maximal serum activity
of amylase was observed after on -d y reperfusion of the pancreas. At that time, th activity of
amyl se was almost thirteen times great r than the value in control animals without i duction of
acute pancreatitis (Figure 6). The greatest activity of lipase was observed after a two-day reperfusion,
reaching a value of more than twenty times greater than in the control group (Figure 7). Then serum
activity of pancreatic enzymes spontaneously and gradually came down. The level of enzymes close
to that in the control group was achieved two weeks following the start of pancreatic reperfusion.
Treatment with acenocoumarol accelerated the normalization of serum amylase activity. This effect
appeared for the first time at the 5th day of reperfusion. The effect of all doses of acenocoumarol was
statistically significant; however, the highest dose of 150 µg/kg/day was the most effective. Four days
later, low doses of acenocoumarol, 50 and 100 µg/kg/day, were still able to reduce the serum level of
amylase, whereas the highest dose of acenoco arol, 150µg/kg/day, was without a notable effect on
this ramete . Two weeks after the start of r perf sion, treatment with ny dos of acenocoumarol
failed to significantly affect th ser activ ty of amylase (Figure 6).
Int. J. Mol. Sci. 2017, 18, 882 8 of 19Int. J. Mol. Sci. 2017, 18, 882 8 of 18 
0
2500
5000
7500
10000
12500
15000
a
a
      C        6 h     1 day          2 days                   5 days                   9 days                 14 days
a
      TIME AFTER INDUCTION OF IR
control (C)
IR
IR + ACN 50
IR + ACN 100
IR + ACN 150
a
a a
a,b
a,b
a
a,b
a,ba,b
a a,c
a aa a
Se
ru
m
 a
ct
iv
ity
 o
f a
m
yl
as
e 
(U
/L
)
 
Figure 6. Influence of treatment with acenocoumarol (ACN) on serum activity of amylase in the 
course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, 
or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental 
group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 
compared to rats with IR without treatment with ACN at the same time of observation. 
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Figure 7. Influence of treatment with acenocoumarol (ACN) on serum activity of lipase in the course 
of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, or 150 
µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group. a p 
< 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to rats 
with IR without treatment with ACN at the same time of observation. 
2.5. Serum Concentration of Interleukin-1β 
The pattern of alterations in the serum concentration of pro-inflammatory interleukin-1β (Figure 
8) in the course of ischemia/reperfusion-induced acute pancreatitis was similar to the type of changes 
Figure 6. Influence of treatment with acenocoumarol (ACN) on serum activity of a ylase in the
course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, or
150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group.
a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to
rats with IR without treatment with ACN at the same time of observation.
Int. J. Mol. Sci. 2017, 18, 882 8 of 18 
0
2500
5000
7500
10000
12500
15000
a
a
      C        6 h     1 day          2 days                   5 days                   9 days                 14 days
a
      TIME AFTER INDUCTION OF IR
control (C)
IR
IR + ACN 50
IR + ACN 100
IR + ACN 150
a
a a
a,b
a,b
a
a,b
a,ba,b
a a,c
a aa a
Se
ru
m
 a
ct
iv
ity
 o
f a
m
yl
as
e 
(U
/L
)
 
Figure 6. Influence of treatment with acenocoumarol (ACN) on serum activity of amylase in the 
course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, 
or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental 
group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 
compared to rats with IR without treatment with ACN at the same time of observation. 
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Figure 7. Influence of treatment with acenocoumarol (ACN) on serum activity of lipase in the course 
of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, or 150 
µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group. a p 
< 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to rats 
with IR without treatment with ACN at the same time of observation. 
2.5. Serum Concentration of Interleukin-1β 
The pattern of alterations in the serum concentration of pro-inflammatory interleukin-1β (Figure 
8) in the course of ischemia/reperfusion-induced acute pancreatitis was similar to the type of changes 
Figure 7. Influence of treat ent with acenocou arol (ACN) on seru activity of lipase in the course
of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, or
150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group.
a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to
rats with IR with ut treatment it ACN at the same time of observation.
A similar ffect of treatment with acenocoumarol was observed in the case of the serum activity
of lipase (Figure 7). The first marked impact of acenocoumarol administration was observed at the
5th day of pancreatic r perfu io . Acenocoumarol given at doses of 100 or 150 µg/kg/day significantly
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reduced the pancreatitis-evoked increase in the serum activity of lipase. In contrast, acenocoumarol
given at a dose of 50 µg/kg/day failed to markedly affect the serum activity of lipase in this time
of observation (Figure 7). Nine days after the start of pancreatic reperfusion, administration of
acenocoumarol given at low doses of 50 or 100 µg/kg/day, significantly reduced the serum activity
of lipase; whereas acenocoumarol given at the highest dose, 150 µg/kg/day, did not significantly
affect this parameter. Moreover, the serum activity of lipase in this group of animals was markedly
higher than in rats treated with lower doses of acenocoumarol (Figure 7). At the 14th day of pancreatic
reperfusion, the serum activity of lipase was low in all groups treated with saline or any dose of
acenocoumarol and was similar to that observed in the control group without the induction of acute
pancreatitis (Figure 7).
2.5. Serum Concentration of Interleukin-1β
The pattern of alterations in the serum concentration of pro-inflammatory interleukin-1β (Figure 8)
in the course of ischemia/reperfusion-induced acute pancreatitis was similar to the type of changes
in the serum activity of lipase. Following the initial increase in its value after the start of pancreatic
reperfusion, with a maximal nearly 4-fold increase observed on day 1, there was observed a gradual
normalization of interleukin-1β concentration throughout the study. Treatment with acenocoumarol
accelerated that process and this effect was statistically significant between the 5th and 9th day of
the experiment in the case of acenocoumarol given at a dose of 100 µg/kg/day (Figure 8). In the
case of acenocoumarol given at a dose of 50 µg/kg/day, a statistically significant effect on the serum
level of interleukin-1β was late and observed only at the 9th day of pancreatic reperfusion. In rats
treated with acenocoumarol given at a dose of 150 µg/kg/day, a statistically significant reduction in
serum interleukin-1β concentration was observed only at the 5th day of reperfusion. On day 14 of
reperfusion, the serum concentration of interleukin-1β was similar in all groups of animals with acute
pancreatitis regardless of the treatment and was similar to that observed in control animals without
the induction of pancreatitis (Figure 8).
Int. J. Mol. Sci. 2017, 18, 882 9 of 18 
in the serum activity of lipase. Following the initial increase in its value after the start of pancreatic 
reperfusion, with a maximal nearly 4-fold increase observed on day 1, there was observed a gradual 
normalization of interleukin-1β concentration throughout the study. Treatment with acenocoumarol 
accelerated that process and this effect was statistically significant between the 5th and 9th day of the 
experiment in the case of acenocoumarol given at a dose of 100 µg/kg/day (Figure 8). In the case of 
acenocoumarol given at a dose of 50 µg/kg/day, a statistically significant effect on the serum level of 
interleukin-1β was late and observed only at the 9th day of pancreatic reperfusion. In rats treated with 
acenocoumarol given at a dose of 150 µg/kg/day, a statistically significant reduction in serum 
interleukin-1β concentration was observed only at the 5th day of reperfusion. On day 14 of reperfusion, 
the serum concentration of interleukin-1β was similar in all groups of animals with acute pancreatitis 
regardless of the treatment and was similar to that observed in control animals without the induction 
of pancreatitis (Figure 8). 
0
50
100
150
200
250
300
aa
      C        6 h     1 day          2 days                   5 days                   9 days                 14 days
a
      TIME AFTER INDUCTION OF IR
control (C)
IR
IR + ACN 50
IR + ACN 100
IR + ACN 150
a
a
a
a
a,b
a
a,b
a,ba,b
a
a
Se
ru
m
 in
te
rle
uk
in
-1
β
 c
on
ce
nt
ra
tio
n 
(p
g/
m
l)
 
Figure 8. Influence of treatment with acenocoumarol (ACN) on serum concentration of interleukin 1β 
in the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 
100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental 
group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 
compared to rats with IR without treatment with ACN at the same time of observation. 
2.6. Pancreatic DNA Synthesis 
The induction of acute pancreatitis resulted in the reduction of pancreatic cell vitality and 
proliferation, measured as the rate of pancreatic DNA synthesis (Figure 9). Maximal reduction in that 
parameter was observed at the 1st day of pancreatic reperfusion, with subsequent gradual recovery 
during the next few days of observation. Treatment with acenocoumarol led to the partial reversion of 
the pancreatitis-evoked drop of pancreatic DNA synthesis and this effect was statistically significant 
between the 5th and 14th day of the study after administration of acenocoumarol at a dose of 100 
µg/kg/day. The therapeutic effect of acenocoumarol given at a dose of 50 µg/kg/day was delayed and 
only visible at the 9th day of pancreatic reperfusion. Administration of acenocoumarol at a dose of 150 
µg/kg/day resulted in a statistically significant improvement of pancreatic DNA synthesis at the 5th 
day of reperfusion, but later this dose of acenocoumarol was without a beneficial effect on this 
parameter (Figure 9). 
Figure 8. Influence of treatment with acenocoumarol (ACN) on serum concentration of interleukin
1β in the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose
of 50, 100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each
experimental group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C),
b p < 0.05 compared to rats with IR without treatment with ACN at the same time of observation.
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2.6. Pancreatic DNA Synthesis
The induction of acute pancreatitis resulted in the reduction of pancreatic cell vitality and
proliferation, measured as the rate of pancreatic DNA synthesis (Figure 9). Maximal reduction
in that parameter was observed at the 1st day of pancreatic reperfusion, with subsequent gradual
recovery during the next few days of observation. Treatment with acenocoumarol led to the partial
reversion of the pancreatitis-evoked drop of pancreatic DNA synthesis and this effect was statistically
significant between the 5th and 14th day of the study after administration of acenocoumarol at a dose
of 100 µg/kg/day. The therapeutic effect of acenocoumarol given at a dose of 50 µg/kg/day was
delayed and only visible at the 9th day of pancreatic reperfusion. Administration of acenocoumarol
at a dose of 150 µg/kg/day resulted in a statistically significant improvement of pancreatic DNA
synthesis at the 5th day of reperfusion, but later this dose of acenocoumarol was without a beneficial
effect on this parameter (Figure 9).Int. J. Mol. Sci. 2017, 18, 882 10 of 18 
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Figure 9. Influence of treatment with acenocoumarol (ACN) on pancreatic DNA synthesis in the 
course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at a dose of 50, 100, 
or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental 
group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 
compared to rats with IR without treatment with ACN at the same time of observation. 
2.7. Plasma D-Dimer Concentration 
Acute ischemia/reperfusion-induced pancreatitis significantly increased the plasma concentration 
of D-Dimer, with the highest, almost a 30-fold increase, seen after one-day pancreatic reperfusion 
(Figure 10). Then the gradual spontaneous normalization of the plasma D-Dimer concentration was 
seen over time, beginning on day 2. Administration of acenocoumarol accelerated the reduction in D-
Dimer and this effect was dependent on the dose of acenocoumarol. After treatment with 
acenocoumarol given at a dose of 150 µg/kg/day, a significant decrease in the D-Dimer concentration 
was apparent by day 5 of pancreatic reperfusion and lasted until the end of the observation time. In 
the case of acenocoumarol given at a dose of 100 µg/kg/day, a statistically significant reduction in the 
pancreatitis-evoked increase in the plasma D-Dimer concentration was observed between the 9th and 
14th day of reperfusion. Acenocoumarol given at a dose of 50 µg/kg/day significantly affected the 
plasma D-Dimer concentration at the 9th and 14th day of pancreatic reperfusion (Figure 10). 
i r . Influence of treat ent ith acenocou arol ( C ) on ancreatic s thesis i t
co rse of isc e ia re erf sio -i ce ac te a creatitis (IR). ACN was given at a dose of 50, 100, or
150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental group.
a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 compared to
rats with IR without treatment with ACN at the same time of observation.
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Figure 10. Influence of treatment with acenocoumarol (ACN) on plasma D-Dimer concentration in 
the course of ischemia/reperfusion-induced acute pancreatitis (IR). ACN was given at the dose of 50, 
100, or 150 µg/kg/day (ACN 50, ACN 100, or ACN 150). Mean ± SEM. n = 8 rats in each experimental 
group. a p < 0.05 compared to control rats without induction of acute pancreatitis (C), b p < 0.05 
compared to rats with IR without treatment with ACN at the same time of observation. 
3. Discussion 
Our present study provided several important findings regarding the role of coagulation in acute 
ischemia/reperfusion-induced pancreatitis and the influence of treatment with acenocoumarol on the 
course of this inflammation. We observed that the development of ischemia/reperfusion-induced 
pancreatitis is associated with the activation of clotting. Six hours after the start of pancreatic 
reperfusion, the plasma D-Dimer concentration reached around a 24-fold higher value than in the 
control group. The maximal level of the D-Dimer concentration was found after a one-day pancreatic 
reperfusion and the spontaneous reduction in this parameter was observed in the subsequent days of 
observation. However, even two weeks after the induction of pancreatitis, the level of D-Dimer was 
higher than in the control group. 
The above changes in plasma D-Dimer concentration were accompanied by an increase in INR. 
Those findings indicate that the course of ischemia/reperfusion-induced acute pancreatitis is 
associated with the activation of coagulation followed by subsequent fibrinolysis and consumptive 
coagulopathy. This observation is in harmony with previous studies showing that coagulative 
disorders are frequent in acute pancreatitis and the determination of coagulative parameters may be 
useful in the prediction of fatal outcome in patients with this disease [10,21]. 
Previous studies have shown that pretreatment with acenocoumarol inhibits the development of 
ischemia/reperfusion-, as well as, cerulein-induced acute pancreatitis [19,20]. However, it must be 
pointed out that patients with acute pancreatitis are usually seen in the hospital several hours or even 
days after the onset of this disease. For this reason, the preventive effect of acenocoumarol against the 
development of acute pancreatitis has only a limited clinical significance. Our current study showed 
that treatment with low doses of acenocoumarol after the development of acute pancreatitis accelerates 
the recovery in ischemia/reperfusion-induced pancreatitis. To the best of our knowledge, this is the first 
report that acenocoumarol exhibits a therapeutic effect in the course of this disease. 
The beneficial effect of acenocoumarol in acute pancreatitis has been evidenced by the 
improvement of the morphological, biochemical, and functional parameters of the pancreatic 
condition. Administration of acenocoumarol after the induction of acute pancreatitis increased INR 
and reduced plasma D-Dimer concentration and those effects were associated with a faster 
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plasma D-Dimer concentration and those effects were associated with a faster normalization of
pancreatic histology leading to earlier reduction and/or elimination of pancreatic edema and
leukocyte inflammatory infiltration of the pancreatic tissue. These effects were accompanied by
a reduction in pancreatic necrosis, vacuolization of acinar cells, and number of hemorrhagic foci. The
therapeutic effect of acenocoumarol was dose-dependent. Acenocoumarol given at the highest dose of
150 µg/kg/dose was the most effective in the treatment of early phase acute pancreatitis. However
later, acenocoumarol given at the highest dose failed to exhibit any beneficial effect on the pancreatic
morphology. Moreover, at the 9 and 14th day of pancreatic reperfusion, acenocoumarol given at a
dose of 150 µg/kg/dose resulted in an increase in the number of hemorrhagic foci in the pancreas.
In contrast, lower doses of acenocoumarol, 50 and 100 µg/kg/dose, were less effective in early phase
acute pancreatitis, but they were still effective at the end of the observation period.
The acenocoumarol-related reduction in inflammatory leukocyte infiltration of pancreatic tissue
was in harmony with a decrease in the pancreatitis-evoked increase in the serum level of interleukin-1β.
In acute pancreatitis, pro-inflammatory cytokines such as interleukin-1β, inerleukin-6, and tumor
necrosis factor-α (TNF-α) are primary produced within the pancreas and subsequently within distant
organs, developing systemic inflammatory response syndrome (SIRS) and multiple organ failure
(MOF) in severe cases of this disease [22,23]. Interleukin-1β plays an essential role in the initiation and
course of inflammatory processes. It exhibits direct pro-inflammatory activity, as well as stimulates
the release of other members of the pro-inflammatory cytokine cascade [24,25]. The severity of AP
is well-correlated with the production of pro-inflammatory cytokines [22]. Previous studies showed
that the administration of the interleukin-1β receptor antagonist prevents a serum rise in interleukin-6
and TNF-α levels, and decreases the severity of acute pancreatitis [26]. It indicates that interleukin-1β
plays an important role in the development and course of this disease.
In the current study, we found an increase in serum concentration of interleukin-1β after the
development of ischemia/reperfusion-induced acute pancreatitis and this effect was followed by
the spontaneous gradual normalization of the serum level of this pro-inflammatory cytokine over
time. The above observation is in agreement with previous reports concerning the serum level of
interleukin-1β in the course of acute pancreatitis [27,28]. A new important finding of our current
study was the discovery that treatment with acenocoumarol led to a significant decrease in the
serum interleukin-1β concentration and limitation of the severity of acute pancreatitis. Moreover,
this observation is in line with previous reports showing that pretreatment with acenocoumarol
before the induction of acute pancreatitis reduces the pancreatitis-evoked increase in the serum level
of interleukin-1β [19,20]. These findings taken together indicate that the acenocoumarol-induced
reduction in the serum level of interleukin-1β is involved in the protective and therapeutic effect of
acenocoumarol in acute pancreatitis.
Further supporting evidence of the therapeutic effect of acenocoumarol in the course of
ischemia/reperfusion-induced acute pancreatitis is related to the reversion of pancreatitis-evoked
increases in the serum concentration of amylase and lipase. Normally, these enzymes are released by
the pancreas into the duodenum. However, in acute pancreatitis, they are ectopically released into the
interstitial space of the pancreas and hence into the circulatory system. For this reason, the serum levels
of amylase and lipase are well-established indices of acute pancreatitis development and severity with
high sensitivity and specificity [28,29]. Active pancreatic enzymes present in the interstitial space of the
pancreas and circulation lead to local and remote organ injury, as well as up-regulate the expression of
adhesion molecules on leukocytes and endothelial cells, leading to an increase in leukocyte-endothelial
interaction and disturbance of organ microcirculation [30].
In our present study, the highest serum activity of amylase was observed after one-day reperfusion
of the pancreas. At that time, the activity of amylase was almost thirteen-fold greater than the value
in control animals without acute pancreatitis. In the case of lipase, maximal serum activity of this
enzyme was observed after a two-day reperfusion, reaching a value of more than twenty times greater
than in the control rats without acute pancreatitis. Then a spontaneous decrease in serum activity of
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amylase and lipase was observed throughout the study, starting on day 2 or 5, respectively. Treatment
with acenocoumarol accelerated the normalization of serum pancreatic digestive enzyme activity.
This effect was statistically significant between the 5th and 9th day of observation in the case of both
enzymes tested.
Adequate blood flow through the organ microcirculation is necessary to provide and sustain
oxygenation and nutrition at a cellular level. Clinical and experimental observations showed that
pancreatic ischemia plays an essential role in the development of acute pancreatitis and progression of
the severity of this disease [31–34]. Pancreatic ischemia/reperfusion injury may be a primary cause
of acute pancreatitis [31–33], but also in acute pancreatitis caused by other, primary non-vascular
mechanisms, the early disturbance of pancreatic circulation is observed [35,36]. The development
of acute pancreatitis is associated with microvascular impairment of the gland with subsequent
formation of thrombi in capillaries, activation of leukocytes, and the release of digestive enzymes
and-pro-inflammatory cytokines [34,35]. These factors act locally in the pancreas, as well as going
into the circulation which can result in systemic effects as systemic inflammatory response syndrome
(SIRS), multiple organ failure (MOF) and ultimately death [22,25]. On the other hand, there are
studies showing that the improvement of pancreatic blood flow inhibits the development of acute
pancreatitis and accelerates recovery in this disease [37–39]. In agreement with previous reports, our
current study confirmed a deleterious impact of acute pancreatitis on pancreatic perfusion. Maximal
reduction of pancreatic blood flow by more than 80% was observed after one-day reperfusion. This
blood flow restriction in the pancreas was temporary and starting from the second day of reperfusion,
this parameter spontaneously and gradually improved reaching almost the control value at the last
day of observation. Administration of acenocoumarol improved pancreatic blood flow in the course
of ischemia reperfusion-induced pancreatitis. This effect was statistically significant at the second
day of reperfusion after administration of acenocoumarol at higher doses of 100 or 150 µg/kg/day.
Acenocoumarol given at a dose of 50 µg/kg/day was able to induce an improvement of pancreatic
blood flow from the 5th day of reperfusion. Improvement of pancreatic blood flow was accompanied
by an improvement of pancreatic morphology and reduction in biochemical markers of inflammation
severity. At the 9th day of reperfusion, acenocoumarol given at doses of 50 or 100 µg/kg/day was
still able to significantly improve pancreatic blood flow; whereas administration of acenocoumarol
at a dose of 150 µg/kg/day was without any beneficial effect on pancreatic blood flow or pancreatic
morphology at that time of observation. These data indicate that appropriate pancreatic blood flow is
necessary for pancreatic recovery and the improvement of pancreatic blood flow is involved in the
therapeutic effect of acenocoumarol in the course of acute pancreatitis.
Cell renewal is essential for the treatment of damaged organs. The cellular rate of DNA synthesis
is an index of cell vitality and proliferation. Several previous studies have demonstrated that acute
pancreatitis, irrespective of etiology, led to an initial reduction in pancreatic DNA synthesis followed
by a subsequent increase in this parameter [40,41]. Our current observations confirmed this pattern
in the ischemia/reperfusion-induced acute pancreatitis in which the severity of pancreatic injury
was very pronounced and pancreatic cell proliferation was initially reduced by approximately 80%.
Moreover, our current study showed that the administration of acenocoumarol after the onset of
acute pancreatitis significantly accelerates the restoration of the appropriate rate of pancreatic DNA
synthesis leading to the acceleration of recovery in this disease. This finding is additional evidence
that acenocoumarol exhibits a therapeutic effect in acute pancreatitis and the mechanism of this effect
involves the improvement of cell vitality and cell proliferation.
Our current study showed that the development of ischemia/reperfusion-induced acute
pancreatitis leads to an increase in the INR value. Administration of acenocoumarol led to an additional
increase in this parameter. These changes in INR may lead to an increase in risk of hemorrhage.
However, intraabdominal hemorrhage was not observed during treatment with acenocoumarol in our
present study. We only found the presence of foci of hemorrhage in histological examinations of the
pancreas and low doses of acenocoumarol reduced the number of these lesions. Also, a small number
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of spontaneous animal deaths was observed only before the second day of pancreatic reperfusion.
Later, when there was a marked increase in INR, further deaths among the animals were not found.
Moreover, the most frequent cause of hemorrhage in the course of acute pancreatitis is not a decrease
in coagulation, but the erosion of small vessels [42]. On the other hand, we used an animal model
of acute pancreatitis. The course of acute pancreatitis in animal models resembles the course of this
inflammation in humans, but it is not identical [43]. The anatomy and physiology of the pancreas in
humans are different from the anatomy and physiology of the pancreas in rats. For this reason, our
study suggests the potential usefulness of acenocoumarol in the treatment of acute pancreatitis, but
further research is required before introducing this type of therapy in this disease.
4. Materials and Methods
4.1. Animals and Treatment
All studies followed an experimental protocol approved by the Committee for Research and
Animal Ethics of the Jagiellonian University and the First Local Commission of Ethics for the Care and
Use of Laboratory Animals in Cracow (Permit Number 4/2013 released on 16 January 2013).
Studies were carried out on 156 male Wistar rats weighing 250–270 g, which were housed in cages
within a windowless colony room. We originally used 152 rats, but 4 animals died before the second
day of pancreatic reperfusion and before intragastric treatment with saline or acenocoumarol. They
died due to abdominal hemorrhage and ascites leading to circulatory insufficiency. For this reason,
4 additional rats were used to reach 8 observations in each experimental group and each endpoint
of the studies. The temperature in the colony room was adjusted at 22 ± 1 ◦C with relative humidity
of 50% ± 10%, and 12:12 h light:dark photoperiod. Following a one-week period of acclimation
to their new environment, rats were randomly assigned to 5 experimental groups, as follows:
(1) sham-operated saline-treated rats (control group); (2) rats treated with saline after the development
of ischemia/reperfusion-induced acute pancreatitis; (3) rats treated with acenocoumarol, given at a
dose of 50 µg/kg/day, after the development of ischemia/reperfusion-induced acute pancreatitis;
(4) rats treated with acenocoumarol given at a dose of 100 µg/kg/day after the development of
ischemia/reperfusion-induced acute pancreatitis; (5) rats treated with acenocoumarol given at a
dose of 150 µg/kg/day after the development of ischemia/reperfusion-induced acute pancreatitis.
The study was terminated after 6 h or 1, 2, 5, 9, or 14 days after the initiation of pancreatic reperfusion
or sham-operation. Each experimental group in each time of observation consisted of 8 rats.
The surgical procedure for the induction of ischemia/reperfusion-induced pancreatitis was
performed according to the method previously described [40]. Rats were fasted with free access to
water for 24 h before the induction of acute pancreatitis or sham-operation. Before the surgery, animals
were anesthetized with ketamine (Bioketan, Vetoquinol Biowet, Gorzów Wielkopolski, Poland) given
intraperitoneally (i.p.) at a dose of 50 mg/kg. After a longitudinal laparotomy, the inferior splenic
artery was clamped down by microvascular clips to induce pancreatic ischemia in the splenic region of
this organ. Thirty min later, microvascular clips were removed to reach pancreatic reperfusion and the
abdominal cavity was closed by sutures. In control sham-operated rats, after longitudinal laparotomy
the mobilization of the pancreas was performed, without clamping any artery.
During the first two days after surgery, animals were monitored every 8 h and received tramadol
(Poltram 100, Polpharma, Starogard Gdański, Poland) given subcutaneously (s.c.) at a dose of
1 mg/kg/dose to minimize pain and distress. Also, immediately after surgery, as well as 12 and 24 h
later, all animals were injected s.c. with 10 mL of Ringer’s solution for the supply of fluids lost during
surgery and postoperative period.
Treatment with saline or acenocoumarol was started 24 h after the beginning of pancreatic
reperfusion. Saline or acenocoumarol (Acenocumarol WZF, Warszawskie Zakłady Farmaceutyczne
Polfa S.A., Warsaw, Poland) were given intragastrically once daily until the day of killing the animals,
which was the last day of treatment. Acenocoumarol was administered at doses of 50, 100, or
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150 µg/kg/day because the earlier study [19] showed that those doses increased the international
normalized ratio (INR) to a value between 2.5 and 3.5. This range of INR is recommended in most
clinical situations associated with hypercoagulation [44].
4.2. Determination of Pancreatic Blood Flow
Rats were again anesthetized with ketamine at the each time of observation. After opening the
abdomen and exposure of the pancreas, blood flow in the splenic region of the pancreas was assessed
using a laser Doppler flowmeter (PeriFlux 4001 Master Monitor, Perimed AB, Järfälla, Sweden),
as described previously in detail [45,46]. Each result was expressed as a percentage of a mean value
obtained in control sham-operated saline-treated rats without the induction of acute pancreatitis.
4.3. Biochemical Analysis
Immediately after the assessment of pancreatic blood flow, samples of blood were withdrawn
from the abdominal aorta. The prothrombin time expressed as the international ratio (INR) was
assessed using Alere INRatio® 2 PT/INR Monitoring Systems and Alere INRatio® PT/INR Monitoring
System Test Strips purchased from Alere San Diego, Inc., San Diego, CA, USA.
The level of plasma D-Dimer concentration was assessed on a coagulation analyzer BCS XP
System (Simens Healthcare Diagnostics, Erlangen, Germany), using an immunoturbidimetric assay
(Innovance D-Dimer Assay, Simens Healthcare GmbH, Marburg, Germany).
Serum activity of pancreatic digestive enzymes, lipase and amylase, was assessed on the Kodak
Ectachem DT II System analyzer (Eastman Kodak Company, Rochester, NY, USA), using Lipa DT, and
Amyl DT Slides (Vitros DT Chemistry System, Johnson & Johnson Clinical Diagnostic, Inc., Rochester,
NY, USA).
The serum level of interleukin-1β (IL-1β) was determined using the Rat IL-1β Platinum Elisa
purchased from Bender MedSystem GmbH, Vienna, Austria.
4.4. Determination of Pancreatic DNA Synthesis
After the blood withdrawal, the pancreas was carefully dissected out from its attachment to
neighboring organs. Samples of pancreatic tissue were taken for study of the pancreatic DNA synthesis
and histological examination. The rate of DNA synthesis was determined by the measurement
of the incorporation of tritium labeled thymidine ([6-3H]-thymidine, 20–30 Ci/mmol, Institute for
Research, Production and Application of Radioisotopes, Prague, Czech Republic) into pancreatic DNA,
as described previously in detail [40,47]. The rate of DNA synthesis was expressed as a number of
tritium atoms disintegrations per minute per microgram DNA (dpm/µg DNA).
4.5. Histological Examination of Pancreatic Damage
Samples of pancreatic tissue were fixed in 10% buffered formalin. Slides were stained with
hematoxylin and eosin, and were examined by two pathologists who were unaware of the treatment
given. As described previously [48], the following histological signs of pancreatic damage were
examined (grading from 0 to 3):
1. pancreatic edema (0—no edema, 1—interlobar edema, 2—interlobar and moderate intralobular
edema, 3—severe interlobula and intralobular edema);
2. leukocyte inflammatory infiltration (0—Absent, 1—scarce perivascular infiltration, 2—moderate
perivascular and scarce diffuse infiltration, 3—abundant diffuse infiltration);
3. vacuolization of acinar cells (0—absent, 1—involving less than 25% of acinar cells, 2—involving
from 25% to 50% acinar cells, 3—involving more than 50% of acinar cells);
4. necrosis of acinar cells (0—absent, 1—involving less than 15% of acinar cells, 2—involving from
15% to 35% acinar cells, 3—involving more than 35% of acinar cells);
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5. hemorrhage (0—absent, 1—from 1 to 2 foci per slide, 2—from 3 to 5 foci per slide, 3—more than
5 foci per slide).
The results of the histological examination results have been shown in Table 1 as a predominant
histological grading (mode) of pancreatic edema, inflammatory infiltration, vacuolization and necrosis
of acinar cells, and hemorrhage in each experimental group. Moreover, we have presented the
representative morphological features of the pancreas and total histological score of pancreatic damage
calculated as the sum of degrees of pancreatic edema, inflammatory infiltration, vacuolization of acinar
cells, necrosis of these cells, and the presence of hemorrhage.
4.6. Statistical Analysis
Statistical analysis was made by analysis of variance followed by Tukey’s multiple comparison
test using GraphPadPrism (GraphPad Software, San Diego, CA, USA). Statistical analysis for each
observation period was calculated separately. Results were presented as means ± SEM. Each
experimental group consisted of eight animals. A difference with a p value of less than 0.05 was
considered significant.
5. Conclusions
In conclusion, we can say that treatment with low doses of acenocoumarol reduces the severity
of ischemia/reperfusion-induced acute pancreatitis in rats and accelerates recovery in this disease.
These findings suggest that treatment with low doses of acenocoumarol may inhibit coagulative
disorders in the course of acute pancreatitis and perhaps it can bring some benefits in the treatment of
acute pancreatitis in humans. However, due to the potential risk of hemorrhage, further research is
needed in this area.
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literature search, collaborated in figure management, and revised the manuscript; Beata Kuśnierz-Cabala carried
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46. Bukowczan, J.; Warzecha, Z.; Ceranowicz, P.; Kuśnierz-Cabala, B.; Tomaszewska, R. Obestatin accelerates
the recovery in the course of ischemia/reperfusion-induced acute pancreatitis in rats. PLoS ONE 2015, 10,
e0134380. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 882 19 of 19
47. Warzecha, Z.; Ceranowicz, P.; Dembinski, M.; Cieszkowski, J.; Ginter, G.; Ptak-Belowska, A.; Dembinski, A.
Involvement of cyclooxygenase-1 and cyclooxygenase-2 activity in the therapeutic effect of ghrelin in the
course of ethanol-induced gastric ulcers in rats. J. Physiol. Pharmacol. 2014, 65, 95–106. [PubMed]
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